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Macrophage infiltration of the kidney is a prominent feature
associated with the severity of renal injury and progressive
renal failure. To determine the influence of macrophages in
renal disease models in the absence of endogenous T and
B cells, we performed adoptive transfer of macrophages into
severe combined immunodeficient (SCID) mice. In this study,
macrophages were isolated from the spleens of BALB/c mice
and stimulated with lipopolysaccharide to induce classically
activated M1 macrophages or with interleukin-4 (IL-4) and
IL-13 to induce alternatively activated M2 macrophages.
These macrophages were then infused into SCID mice with
adriamycin nephropathy; an in vivo model of chronic
inflammatory renal disease analogous to human focal
segmental glomerulosclerosis. Mice infused with M1
macrophages had a more severe histological and functional
injury, whereas M2 macrophage-induced transfused mice
had reduced histological and functional injury. Both M1 and
M2 macrophages localized preferentially to the area of injury
and maintained their phenotypes even after 4 weeks. The
protective effect of M2 macrophages was associated with
reduced accumulation and possibly downregulated
chemokine and inflammatory cytokine expression of the host
infiltrating macrophages. Our findings demonstrate that
macrophages not only act as effectors of immune injury but
can be induced to provide protection against immune injury.
Kidney International (2007) 72, 290–299; doi:10.1038/sj.ki.5002275;
published online 18 April 2007
KEYWORDS: macrophages; cell transfer; chronic renal disease
In human and animal renal disease, macrophage accumula-
tion correlates with the degree of histological and functional
injury, suggesting that macrophages play a role in renal
injury.1–3 Adriamycin (ADR)-–induced nephropathy (AN) is
a robust experimental analog of human focal segmental
glomerulosclerosis, characterized by changes in both tubulo-
interstitial and glomerular compartments. This animal model
of AN was initially established in rat. We previously
developed a model of AN in BALB/c mouse, which was
similar to AN in rat. More recently, a model of AN was
developed in severe combined immunodeficiency (SCID)
mice which are homozygous for an autosomal recessive
mutation leading to the absence of lymphocytes. In spite of
the absence of lymphocytes, SCID mice developed functional
and histological changes similar to those of immunocompe-
tent mice, yet with increased sensitivity to ADR-induced
injury.4 Antibody depletion of macrophages (using the
monoclonal antibody ED7) resulted in reduced renal injury
in AN.5 Ablation of macrophages in murine crescentic
glomerulonephritis also reduced renal injury and improved
renal function.6 Our recent studies in SCID mice (deficient in
T and B cells) and NOD/SCID mice (deficient in T, B, and
NK cells) have shown that neither lymphocytes nor NK cells
are necessary for induction of this model, consistent with a
primary role for macrophages as key effectors in AN.7
Other studies have instead shown a beneficial role for
macrophages, which depends on their phenotype and
location and the nature of injury.8–11 In mice with unilateral
ureteric obstruction (a model of chronic renal injury)
reconstituted with bone marrow of angiotensin II type 1
receptor gene knockout mice, infiltrating macrophages were
shown to play an antifibrotic role.12 Macrophages transfected
with adenovirus to express IL-4 have been shown to reduce
renal inflammation in rats with nephrotoxic nephritis.13
The capacity to modify macrophage function has been
demonstrated in a number of studies in vitro.14–21 Lipopoly-
saccharide and proinflammatory stimuli such as interferon-g
or tumor necrosis factor-a (TNF-a) induce classically
activated macrophages (M1 macrophages), characterized by
antimicrobial and cytotoxic properties, which underlie their
role in host responses to infection or autoimmune disease,
whereas exposure to IL-4 and IL-13 results in alternative
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activation of macrophages (M2 macrophages). Recent studies
have shown that these alternatively activated cells produce
several components involved in the synthesis of extracellular
matrix, suggesting that their primary role may involve tissue
repair rather than microbial killing.22 M2 macrophages have
been studied extensively in vitro with respect to their
suppressive activity, secretion of anti-inflammatory cytokines
and ability to modulate wound healing and angiogenesis.23
However, adoptive transfer of cytokine-programmed M2
macrophages has not been explored in vivo.
We hypothesized that macrophages could be polarized
in vitro in a way that would result in a persistent in vivo
functional phenotype. Using SCID mice, we evaluated the
effect of different macrophage phenotypes on tissue injury
in vivo in the absence of T and B cells. Transfusion of M1
macrophages not surprisingly exacerbated AN, whereas M2
macrophages were shown to protect against in vivo renal
injury in the presence of host macrophages suggesting they
could exert a dominant protective effect.
RESULTS
Macrophage purity and phenotype
Macrophages were isolated from the spleen of BALB/c mice
using a magnetic bead isolation kit with CD11b beads. The
fraction of CD11b-positive cells from fresh spleens following
purification was 96%, whereas CD11c (dendritic cell marker),
CD19 (B-cell marker), and CD49b (NK-cell marker)-positive
cells accounted for o1% of the purified suspension
(Figure 1).
There was strong expression of CCL3, inducible nitric
oxide synthase (iNOS), TNF-a, CD86, and major histology
complex class II by M1 macrophages, but not by M0
(nonstimulated macrophages) or M2 macrophages. In
contrast, expression of CCL17, mannose receptor, and
secretion of IL-10 were seen with M2 macrophages, but not
M1 macrophages. Trace expression of mannose receptor was
seen with M0 macrophages (Figure 2).
Renal function
We sought to investigate the effect of adoptive transfer of ex
vivo-modulated macrophages in established renal injury. AN
was induced in SCID mice by tail-vein injection of 5.2 mg/kg
ADR. Macrophages (M0, M1, or M2 – see Materials and
Methods) were infused by tail-vein injection 5 days after
ADR. Serum creatinine and urine protein were assessed at
days 14, 21, and 28 after ADR, and were significantly worse
following transfusion with M1 macrophages, significantly
better with M2 macrophages, and unchanged with M0
macrophages compared with AN alone at day 28 (Figure 3).
Transfusion of culture medium from final stages of M0, M1,
or M2 macrophage preparation (before their transfusion)
had no significant effect on kidney function or structure in
normal or AN mice (data not shown).
Renal histology
Marked renal injury was seen at week 4 in AN, characterized
by glomerular sclerosis, tubular atrophy, and interstitial
fibrosis with significant mononuclear cell infiltration. Renal
injury was increased greatly in AN mice transfused with M1
macrophages compared with control AN mice. Conversely,
injury was significantly reduced in mice transfused with M2
macrophages, whereas there were no significant changes in
mice transfused with M0 macrophages. The number of
points within trichrome-positive vs trichrome-negative
cortical fields were counted at  200 magnification from
randomly selected 10 fields, and expressed as a percentage. In
parallel with the tubulointerstitial injury findings, M1
macrophage transfusion induced more fibrosis
(45.474.5%; Po0.01) as compared with AN control
(29.275.1%) and AN transfused with M0 macrophages
(27.773.9%), and M2 macrophage transfusion significantly
suppressed the development of interstitial fibrosis
(15.173.1%; Po0.01 vs other three groups) (Figure 4a–e).
Immunohistology of macrophages
Tissue sections were double stained with immunofluorescent
antibodies F4/80 for macrophages and Ki67 for proliferative
cells. Very few double-positive cells were observed. Single
immunohistochemical staining with F4/80 and Ki67 showed
an increase in the number of total F4/80-positive cells and
Ki67-positive nuclei in the M1 transfused mice and a
significant reduction in the M2 transfused mice compared
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Figure 1 | Purity of isolated macrophages separated from fresh spleen. This shows a representative flow cytometry analysis of
CD11b, CD11c, CD19, and CD49b-positive cell populations after antibody-coated magnetic beads separation. Data shown are from one
of three independent experiments.
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with the M0 transfused mice (Figure 5). The quantitation of
these positive cell numbers is shown in Table 1.
In vivo tracking of transferred macrophages
One million fluorescently labeled M0, M1, or M2 macro-
phages were injected via tail vein at day 5 after ADR or into
control normal mice. Fluorescently labeled cells were
distributed to kidney, spleen, and liver of AN mice 24 h after
transfer (day 6). Interestingly, there was no trace of
fluorescently labeled cells in lung and heart 24 h after
transfusion. Few of these cells were seen in spleen and liver
at days 14 and 28 (Figure 6a), whereas transfused macro-
phages accumulated progressively in kidneys up to day 28
after ADR. A reduction of native macrophage infiltration was
observed in mice transfused with M2 macrophages. (Figure
6b–f).
Persistence of macrophage phenotype after prolonged
culture in vitro
The above in vivo experiment demonstrated renal accumula-
tion of transfused macrophages and especially M1 macro-
phages as long as 4 weeks after transfusion. The number and
viability of macrophages were examined. The cell numbers
decreased to around half those of the initial seeding (from
1.3 107 to 6.5 106) after 28 days culture in vitro. The
viability of the cells as defined by trypan blue staining was
approximately 85% after 28 days of in vitro culture. Similarly,
the proportion of apoptotic cells after 28 days increased to
18–25% by annexin V staining. Therefore, we next tested the
stability of macrophage phenotype over time. We compared
the expression of CCL3 and iNOS mRNA by freshly separated
M1 to that of M1 macrophages cultured for 4 weeks, using
real-time polymerase chain reaction (PCR). In vitro expres-
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Figure 2 | Macrophage phenotypes. Macrophage phenotypes under different incubation conditions were confirmed in all experiments
by (a) FACS analysis of CD86 and major histology complex class II; (b) polymerase chain reaction for mRNA expression of iNOS, CCL3,
CCL17, and mannose receptor; and (c) western blot of IL-10 and TNF-a.
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sion of CCL3 and iNOS by M1 macrophages was maintained
for 4 weeks. Similarly, the expression of CCL17 and mannose
receptor mRNA by M2 macrophages was maintained for
4 weeks (Figure 7).
In vivo properties of kidney macrophages after transfusion
Macrophages were isolated from AN kidneys at day 28, using
saline perfusion and CD11b beads. Macrophage iNOS, CCL3,
CCL17, mannose receptor, CCL2, and TNF-a mRNA
expression were assessed. There was a trend toward decreased
total macrophage mRNA expression of CCL2 and TNF-a
after M2 macrophage transfusion. In contrast, renal macro-
phage mRNA expression of iNOS, CCL2, and TNF-a
expression was significantly upregulated after M1 macro-
phage transfusion. Renal macrophage mRNA expression of
CCL17 at day 28 was upregulated after M2 macrophage
transfusion (Figure 8). No difference was seen in expression
of mannose receptor and CCL3 among all groups (data not
shown).
DISCUSSION
In this study we examined the effect of transfused macro-
phages programmed ex vivo by cytokines, in a model of
chronic inflammatory renal disease (AN). Transfusion of M0
macrophages had no significant effect on renal injury. M1
macrophages promoted both histological damage and
functional impairment. However, M2 macrophages strongly
protected renal structure and function. Once modified to a
M1 or M2 phenotype, macrophages maintained their
properties in vitro for up to 4 weeks. This provides proof
of the potential of macrophages cultured with IL-4 and IL-13
as a treatment for chronic renal disease.
The harmful effect of preactivated macrophages has been
demonstrated previously, in models of kidney disease.
Ikezumi et al.24 demonstrated that adoptive transfer of
macrophages incubated with interferon-g caused a twofold
increase in the degree of proteinuria and glomerular cell
proliferation compared with transfer of unstimulated macro-
phages in a cognate model of renal disease, antiglomerular
basement membrane nephritis. This finding is in line with
our results that demonstrated an augmentation of renal
damage by M1 macrophages in AN in SCID mice, a model of
innate immune renal injury.
Ikezumi et al.,25 in a separate study, observed induction of
proteinuria and mesangial cell proliferation by adoptive
transfer of M0 macrophages during the acute stage of rat
accelerated antiglomerular basement membrane disease. The
absence of such an effect of M0 macrophages in AN may
relate to the primary cellular nature of the inflammation in
AN vs the antibody-driven pathology of antiglomerular
basement membrane disease where even M0 macrophages
may be activated through Fc receptors by pathogenic
antibodies.
The most striking finding in these studies is that M2
macrophages protected against both structural and func-
tional damage in AN, a protective effect which has only
previously been demonstrated in vitro.10,26,27 Stability of
macrophage phenotype after initial cytokine exposure has
been reported previously and parallels that found in
lymphocyte polarization to Th1 and Th2 cells.28,29 Other
studies have suggested that microenvironment can reprogram
the functional phenotype of macrophages.30 Our results
provide in vivo support for the suggestion that macrophage
phenotype persists despite the microenvironment.
We found that both M1 and M2 macrophages trafficked to
inflamed kidneys in AN. This suggests that the expression of
chemokine and other trafficking receptors by these macro-
phages has the potential to deliver them to sites of
inflammation. We have previously shown in several models
of renal disease the expression of a variety of chemokines
including the CCL2, a monocyte recruiting chemokine. This
targeting to the inflamed organ enhances efficacy relative to
the number of cells transferred and provides promise for
potential clinical studies.
Other strategies to ameliorate impaired renal function in
animal models have included direct cytokine gene transfer,
chemokine blockade, or macrophage manipulation.31–36
Renal adoptive transfer of macrophages genetically modified
to express either IL-4, IL-10, or IL-1 receptor antagonist
reduced macrophage infiltration and renal injury in animal
nephritis models.13,37,38 More recently, macrophages in which
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Figure 3 | Serum Creatinine and 16 h urine protein at day 28.
The values represent the mean7s.e.m. of evaluations from each
group (n¼ 7 per group). *Po0.05 vs other three groups, **Po0.01
compared with other three groups.
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the nuclear factor-kB pathway was inhibited by transduction
with dominant-negative inhibitory kB developed anti-
inflammatory properties and were able to reduce glomerular
injury in nephrotoxic serum nephritis.39 Cytokine manipula-
tion of macrophages to the M2 phenotype provides many of
the advantages of gene transduction without the associated
risks. The advantages of this method include the simplicity of
in vitro macrophage modulation by cytokines, and the
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Figure 4 | Effect of M0, M1, and M2 macrophages transfusion on histological injury and development of renal fibrosis.
(a–d) Representative periodic acid–Schiff- and trichrome-stained sections of renal cortices at day 28 (original magnification  200).
(a) Saline-injected AN mice, (b) AN mice transfused with M0 macrophages, (c) AN mice transfused with M1 macrophages, (d) AN mice
transfused with M2 macrophages. (e) Kidney injury was assessed semiquantitatively (periodic acid–Schiff) and for fibrosis by point counting
(trichrome). Each evaluation represents the mean7s.e.m. *Po0.05 vs other three groups (n¼ 7 per group).
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Figure 5 | Representative double immunofluorescence staining of F4/80 and Ki67 and single immunohistological staining of F4/80
and Ki67 on kidney tissue frozen sections at day 28 (original magnification  400). Numerous cells expressing Ki67þ (green nucleus)
or F4/80þ (red membrane) cells and very few cells co-expressing F4/80þ Ki67þ (green nucleus surrounded by red membrane) were
observed on double immunofluorescence staining sections for all four groups. Single staining of F4/80 or Ki67 on immunohistological
staining sections disclosed a relationship of positive cell numbers and renal injury severity. (a) Saline-injected AN mice, (b) AN mice
transfused with M0 macrophages, (c) AN mice transfused with M1 macrophages, (d) AN mice transfused with M2 macrophages.
The quantitation of these positive cell numbers is shown in Table 1 (n¼ 7 per group).
294 Kidney International (2007) 72, 290–299
o r i g i n a l a r t i c l e Y Wang et al.: Programmed macrophages in AN
AN+vehicles AN+M0 AN+M1 AN+M2
**
*
b c
d e
Kidney Liver Spleen
Day 6
Day 14
N
at
ive
 m
a
cr
o
ph
ag
es
(po
int
s)
80
70
60
50
40
30
20
10
0
a
f
Figure 6 | Tracking of transfused macrophages in vivo during progression of AN (original magnification  200). (a) Representative
fluorescence photomicrographs showing M1 macrophage localization in kidney, spleen, and liver at day 6 and day 14 after ADR, following
transfusion with M1 macrophages at day 5. (A similar distribution of M0 and M2 macrophages was seen after their transfusion; not shown.)
(b) Representative immunofluorescence staining of macrophages on kidney sections at day 28. Cells fluorescing orange are double positive
for fluorescent dye and F4/80, whereas cells fluorescing green are F4/80-positive cells, stained with immunofluorescent F4/80 FITC.
(b) Saline-injected AN mice, (c) AN mice transfused with M0 macrophages, (d) AN mice transfused with M1 macrophages, (e) AN mice
transfused with M2 macrophages (n¼ 7 per group). (f) The area fluorescing green representing F4/80-stained macrophages was assessed
quantitatively by point counting. Each evaluation represents the mean7s.e.m of averaged number of points per field from each animal.
*Po0.05 vs other groups (n¼ 7 per group), **Po0.01 vs other groups (n¼ 7 per group).
Table 1 | Quantitative analysis of F4/80-positive and Ki67-positive cells
AN+vehicle AN+M0 AN+M1 AN+M2
F4/80-positive cells 84.1777.73 86.6778.89 126.71717.46a 50.8376.35b
Ki67-positive cells 15.3772.18 16.9872.73 22.6873.54b 9.2371.56b
The values represent the mean7s.d. of positive cells/ 400 field.
aPo0.01 compared with other three groups.
bPo0.05 compared with other three groups.
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effectiveness of intravenous administration without the need
for specialized delivery. Most important is the fact that it
avoids the limitations of gene therapy including gene delivery
and risks of the viral vector.40,41
Previous studies of renal macrophage phenotype have
studied the composition of the macrophage population. In
the anti-Thy1.1 model of proliferative nephritis, 70% of
macrophages infiltrating glomeruli demonstrated a M1
phenotype and 30% behaved as if activated by transforming
growth factor-b.42 Our study was able to do this in a very
informative way. Having demonstrated that short-term
induction of M1 or M2 phenotype led to a persistence of
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Figure 8 | In vivo properties of kidney macrophages in AN at day 28. The expression of iNOS, CCL17, CCL2, and TNF-a mRNA was assessed
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these characteristics for up to 4 weeks in culture, we
evaluated the effect of transfer of these cells on host
macrophages. M1 transfused mice exhibited skewing of
expression of host macrophage-related molecules to that of
the transfused population. However, M2 macrophage trans-
fusion caused an apparent (nonsignificant) decrease in
expression of CCL2 and TNF-a and a significant increase
in expression of CCL17 in total macrophages suggesting that
in addition to their possible effects on other cells M2
macrophages could skew the host macrophage phenotype.
M1 macrophages are known to have direct effects on renal
parenchymal cells via the release of NO and other
mediators,43 whereas it is unknown whether M2 macro-
phages can directly affect the parenchyma. Thus, it is possible
that the protective effect of M2 macrophages may involve a
direct or indirect effect on renal parenchymal cells, in
particular tubular epithelial and mesangial cells.
In conclusion, this study provides the direct evidence that
macrophage modulation ex vivo by cytokines to an anti-
inflammatory phenotype (M2), is an effective strategy for
treating experimental chronic inflammatory renal disease.
The regulatory effects of M2 macrophage were shown to be
target-specific, sustainable, and dominant.
MATERIALS AND METHODS
AN murine model
Six- to eight-week-old male SCID and BALB/c mice obtained from
the Animal Resources Centre (Perth, Australia) were used in this
study. The Animal Ethics Committee of Westmead Hospital
approved all procedures. Dose-finding studies defined an optimal
dose of 5.2 mg/kg body weight of ADR (Pharmacia & Upjohn Pty
Ltd., Australia). ADR was injected once via the tail vein of each non-
anesthetized SCID mouse.44
Macrophage separation from spleen and ex vivo culture
conditions for M1 and M2 macrophages
BALB/c mice splenocytes were harvested and washed in ice-cold
RPMI 1640 medium (Invitrogen, Mount Waverly, Australia). Tissue
was triturated with the sterile syringes, and the resulting cell
suspension was filtered through 40-mm nylon mesh (BD Biosciences,
North Ryde, Australia) and then incubated at 371C for 30 min. The
adherent cells were harvested and purified by MACS CD11bþ
MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany, Bergisch
Gladbach). These spleen-derived macrophages were rinsed three
times with RPMI 1640 medium and further processed to become
M0, M1, and M2. Macrophages cultured in the normal medium for
48 h were defined as M0; macrophages undergoing a 2-h incubation
with lipopolysaccharide (2.5 mg/ml) and then cultured in normal
medium for another 46 h were defined as M1; and macrophages
undergoing the incubation with IL-4/13 (10 ng/ml each) for 48 h
were defined as M2. Lipopolysaccharide was purchased from Sigma-
Aldrich (Castle Hill, Australia), and IL-4 and IL-13 were purchased
from Invitrogen.
Analysis of macrophage apoptosis
Apoptosis was analyzed by flow cytometric detection of fluorescein
isothiocyanate (FITC)-labeled annexin V (BD, North Ryde,
Australia) according to the company’s manual. In brief, collected
macrophages were washed twice with cold phosphate-buffered saline
and then cells were resuspended in 1 binding buffer at a
concentration of 1 106 cells/ml. Then 100 ml of the solution
(1 105 cells) was incubated for 15 min at room temperature
(251C) in the dark after adding 5 ml of annexin V-FITC and 5 ml of
propidium iodide. After that, 400 ml of 1 binding buffer was added
to each tube. Flow cytometric analysis was performed with a FACS
Calibur flow cytometer (BD, Mountain View, CA, USA) and 10 000
events were acquired from each sample. Data were collected and
analyzed with CellQuest 3.1 software (BD).
Isolation of infiltrated macrophages from mouse kidney
Warm saline (371C) was perfused to the right heart atrium
under anesthesia to remove peripheral blood within mouse kidney.
Kidney tissue was then triturated in RPMI 1640 medium with the
sterile syringes, and the resulting cell suspension was filtered
through 40-mm nylon mesh. Mononuclear cells were separated
using a step-gradient sucrose separation procedure (Lymphoprep,
Pharmacia, Uppsala, Sweden). Purification of macrophages
was performed by positive selection using MACS CD11bþ
MicroBeads.
Flow cytometry
Isolated macrophages were suspended in FACS wash buffer
(phosphate-buffered saline with 1% fetal calf serum) and Fc block
(eBiosciences, San Diego, CA, USA). Cells were stained with FITC-
conjugated anti-mouse CD11b, FITC-conjugated anti-mouse CD
49b, FITC-conjugated anti-mouse CD11c, PE-conjugated anti-
mouse CD19, PE-conjugated anti-mouse major histology complex
class II, and PE-Cy5 anti-mouse CD86 (eBiosciences, USA). All the
samples were then analyzed by flow cytometry on a Beckton
Dickinson FACScan (BD Biosciences). At least 1 105 events were
collected per sample.
Macrophage labeling and adoptive transfer to SCID mice
For in vivo study, three different phenotypes of macrophages were
labeled with red fluorescent membrane label, DiI (Invitrogen)
according to the manufacturer’s instructions, and harvested into
serum-free medium immediately before injection. DiI is a lipophilic
membrane stain that diffuses laterally to stain the entire cell. It is
weakly fluorescent until incorporated into membranes. This red
fluorescent dye, which is spectrally similar to tetramethylrhodamine,
is often used as a long-term tracer for neuronal and other cells.45 In
brief, 50 mg DiI was dissolved into 50 ml pure ethanol. To a one
–million-cell suspension in 1 ml RPMI 1640, 4 ml DiI was added for
10 min incubation at 371C followed by 15 min incubation at 41C.
Macrophage viability and phenotype did not change with labeling.
One million cells were transferred into treated SCID mice by a single
tail-vein injection at day 5 after ADR. Twenty-one mice in each of
groups A (ADRþ saline), B (ANþM0 macrophages), C (ANþM1
macrophages), and D (ANþM2 macrophages) were caged accord-
ing to their groups. Seven mice in each group were killed on days 6,
14, and 28 after ADR.
Then kidney sections stained with F4/80 FITC fluorescence were
visualized under fluorescence microscopy (magnification  200).
The green fluorescent cells represent F4/80 FITC staining macro-
phages and the orange fluorescent cells were considered to be
transfused macrophages. F4/80 FITC-stained macrophages were
assessed and quantified by point counting using Image J software
(NIH, USA). Randomly, 10 nonoverlapping cortical fields from each
kidney section of seven separate animals per group were selected for
analysis.
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Histology and immunohistochemistry
Kidneys were rapidly removed on days 6, 14, and 28. Coronal
sections of renal tissue were immersion-fixed in 10% neutral-
buffered formalin and embedded in paraffin. Sections 5-mm thick
were stained with periodic acid–Schiff or trichrome. The remaining
cortex of the same kidney was frozen in liquid nitrogen and used for
RNA analysis and immunohistochemistry. To evaluate the degree of
renal injury, 20 fields of view/section at a magnification of  200
were assessed and the degree of renal injury was estimated by
evaluating the percentage of renal injury per field and was graded on
a scale of 0–4:0, normal glomeruli, tubules, and interstitial volume;
0.5, small focus of glomerular and tubular injury and interstitial
volume; 1, involvement ofo10% of the cortex; 2, involvement of up
to 25% of the cortex; 2.5, involvement of 26–50% of the cortex; 3,
51–75% of the cortex; and 4, extensive damage involving 475% of
the cortex.46 Quantitative analysis of glomerulosclerosis was
performed using a modification of the technique described by
Saito et al.47 The degree of sclerosis was scored from 0 to 4 in each of
20 glomeruli from periodic acid–Schiff-stained sections and
averaged for each mouse. Interstitial fibrosis was assessed and
quantified on trichrome-stained sections by point counting using
Image J software in each of 10 nonoverlapping cortical fields from
the cortical region for analysis. Points falling within blue areas
(fibrosis) were considered as positive. Scores derived from 10 fields
per kidney section were averaged, and mean scores were from seven
separate animals per group.
For immunohistochemical staining of macrophages, rat anti-
mouse F4/80 (eBiosciences) or rabbit anti-Ki67 (Lab Vision,
Fremont, USA) was used as the primary antibody and biotinylated
rabbit anti-rat Ig (Dako Corporation, Botany, Australia) was
used as the secondary antibody. Kidney sections were placed in
OCT (Sakura Fintek Inc., Torrance, USA). Sections of 5 mm
were cut, dried overnight, and fixed in cold acetone for
8 min. Endogenous peroxidase activity was blocked by 0.3% (v/v)
H2O2 solution for 15 min when incubating the slides. Biotin
Blocking System (Dako, Botany, Australia) was used to block
endogenous avidin-binding activity. Normal rat immunoglobulin
was used for control sections. Sections were incubated with
secondary antibodies, ABC, and 3,3-diaminobenzidine substrate-
chromogen solution (Dako) were applied and then washed. Slides
were counterstained with hematoxylin (Sigma, Castle Hill, Aus-
tralia). For assessment of interstitial infiltration, positively stained
cells located in the tubular interstitial area only were counted from
more than 20 random cortical fields (magnification  400) in each
section, and the numbers averaged for each section, as described
previously.44
Immunofluorescence staining for macrophages was performed
on frozen slides prepared as for immunohistochemical staining.
FITC-conjugated anti-Rabbit or phycoerythrin-conjugated anti-Rat
antibody (eBiosciences) was used as the second antibody.
Western blot analysis
Cells were lysed in sodium dodecyl sulfate sample buffer (2%
sodium dodecyl sulfate, 10 mM Tris–HCl (pH 6.8), and 10% (v/v)
glycerol) and equal amounts of proteins from various treatments
were subjected to immunoblotting with the IL-10 (1:1000 dilution;
R&D, Gymea, Australia), TNF-a (1:2500 dilution; R&D), and b-
actin (1:4000 dilution; Sigma). Immunoreactivity was determined
by horseradish peroxidase-conjugated donkey anti-goat antibody
and an enhanced chemiluminescence reaction (Pierce, Rockford,
USA).
Renal function
All urine and blood specimens were analyzed by the Institute of
Clinical Pathology and Medical Research (Westmead Hospital),
using a BM/Hitachi 747 analyzer (Tokyo, Japan).
Isolation of total RNA, synthesis of cDNA, reverse
transcription-PCR, and quantitative real-time PCR
Cells were homogenized and the total RNA was isolated using RNeasy
Mini Kit (Qiagen, Australia). cDNA was synthesized with a reverse
transcriptase reaction using a standard technique (SuperscriptTM First
Strand Synthesis System for RT-PCR; Invitrogen). The PCR primer
sequences used in this study were designed using Oligoperfect software
(Invitrogen website) and are presented in Table 2. Primers were
designed to span intron–exon boundaries. For reverse trancription-
PCR, a 0.2mg portion of cDNA was used in a 25ml PCR mixture with
2 ng/ml of each primer and 2 U of Taq DNA polymerase (Roche, Dee
Why, Australia). Housekeeping gene 18S was used as the endogenous
control. PCR products after amplification were analyzed by 1.5%
agarose gel electrophoresis. For real-time PCR, mRNA levels were
quantified using the Rotogene-3000 Real-Time Thermo cycler (Corbett
Research, Mortlake, Australia). PCR mixtures containing 0.3mM
primers in 25ml final SYBR mastermix (Invitrogen) were cycled for
2 min at 501C, 2 min at 951C followed by 40 cycles of 15 s at 951C, 30 s
at 551C, and 30 s at 721C. The normalized value for mRNA expression
in each sample was calculated as the relative quantity of relevant
primers divided by the relative quantity of the housekeeping gene 18S.
Statistical analysis
Renal functional data (serum creatinine and urine protein) were log-
transformed before analysis to stabilize the variance. The statistical
package SPSS for windows version 14 was used to analyze the data.
Analysis of variance was used to test for an association between the
log-transformed outcome and treatment (one-way analysis of
variance). The pairwise comparisons between treatments were
adjusted for multiple comparisons using the Bonferroni technique.
Other data analyses were performed directly by one-way analysis of
variance for multiple comparisons of parametric data, and the
Kruskal–Wallis test for nonparametric data. Results are expressed as
the group mean7s.e.m. A Po0.05 was considered statistically
significant.
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Table 2 | Real-time PCR primers and products
Gene Primer sequence (50y30) Product
CCL3 (F) tgcccttgctgttcttctct 124
CCL3 (R) gatgaattggcgtggaatct
iNOS (F) caccttggagttcacccagt 170
iNOS (R) accactcgtacttgggatgc
CCL17 (F) tgcttctggggacttttctg 147
CCL17 (R) catccctggaacactccact
Mannose receptor (F) caaggaaggttggcatttgt 111
Mannose receptor (R) cctttcagtcctttgcaagc
TNF-a (F) gctgagctcaaaccctggta 118
TNF-a (R) cggactccgcaaagtctaag
CCL2 (F) cccaatgagtaggctggaga 125
CCL2 (R) tctggacccattccttcttg
iNOS, inducible nitrogen oxide synthase; PCR, polymerase chain reaction;
TNF-a, tumor necrosis factor-a.
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